Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.539 billion RMB, representing a 5.95% year-on-year increase [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a growth of 19.17% year-on-year [1] - Basic earnings per share were reported at 0.67 RMB [1] Group 2: Sales and Market Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around specialized departments [1] - There is a focus on product line segmentation and enhanced management through sales divisions, improving the professional capabilities and focus of the sales team [1] - The company is emphasizing collaborative sales across key surgical procedures, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]